Telavancin-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Telavancin

Published:2009-12 Issue:12 Volume:8 Page:929-930
ISSN:1474-1776
Container-title:Nature Reviews Drug Discovery
language:en
Short-container-title:Nat Rev Drug Discov

Author:

Corey G. Ralph,Stryjewski Martin E.,Weyenberg Wim,Yasothan Uma,Kirkpatrick Peter

Publisher

Springer Science and Business Media LLC

Subject

Drug Discovery,Pharmacology,General Medicine

Link

http://www.nature.com/articles/nrd3051.pdf

Reference16 articles.

1. Van Bambeke, F. Glycopeptides in clinical development: pharmacological profile and clinical perspectives. Curr. Opin. Pharmacol. 4, 471–478 (2004).

2. Leadbetter, M. R. et al. Hydrophobic vancomycin derivatives with improved ADME properties: discovery of telavancin (TD-6424). J. Antibiot. 57, 326–336 (2004).

3. Hegde, S. S. et al. Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against Gram-positive bacteria. Antimicrob. Agents Chemother. 48, 3043–3050 (2004).

4. Food and Drug Administration. FDA labelling information. FDA website [ online ] (2009).

5. Higgins, D. L. et al. Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 49, 1127–1134 (2005).

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Semisynthesis: An Essential Tool for Antibiotics Drug Discovery;ChemistrySelect;2024-06-18

2. Prominent Classes of Antibiotics and their Mechanism of Resistance against Methicillin-Resistant Staphylococcus aureus;Journal of Pure and Applied Microbiology;2024-03-01

3. Mesoporous silica nanoparticles: An emerging approach in overcoming the challenges with oral delivery of proteins and peptides;Colloids and Surfaces B: Biointerfaces;2023-12

4. C–H modification of natural products: a minimalist enabling tactic for drug discovery, API processing and bioconjugation;Chemical Communications;2023

5. Resistance-proof antimicrobial drug discovery to combat global antimicrobial resistance threat;Drug Resistance Updates;2023-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3